New York, NY (PRWEB) December 08, 2013
IRA Financial Group, the leading provider of solo 401k plans announces the introduction of its special SEP IRA rollover self-directed solo 401(k) plan for the self-employed and small business owner. The special self-directed solo 401(k) Plan will be geared towards self-employed individuals looking to rollover a SEP IRA into a self-directed retirement structure. “Our special open architecture self-directed solo 401(k) plan will allow SEP IRA holders to rollover their SEP IRA funds into a new solo 401(k) Plan without tax or penalty, “ stated Susan Glass, a retirement tax specialist with the IRA Financial Group.
A solo 401(k) plan, also known as an individual 401k Plan, is an IRS approved retirement plan, which is suited for business owners who do not have any employees, other than themselves and perhaps their spouse. The “one-participant 401(k) plan” or individual 401(k) Plan is not a new type of plan. It is a traditional 401k plan covering only one employee. Unlike a Traditional IRA, which only allows an individual to contribute $5500 annually or $6500 if the individual is over the age of 50, a solo 401k Plan offers the Plan participant the ability to contribute up to $56,500 each year. Before the Economic Growth and Tax Relief Reconciliation Act of 2001 (EGTRRA) became effective in 2002, there was no compelling reason for an owner-only business to establish a solo 401(k) Plan because the business owner could generally receive the same benefits by adopting a profit sharing plan or a SEP IRA. After 2002, EGTRRA paved the way for an owner only business to put more money aside for retirement and to operate a more cost-effective retirement plan than a Traditional IRA or 401(k) Plan.
According to Ms. Glass, the main reason the solo 401(k) Plan has become more popular than a SEP IRA is that one can reach their maximum annual contribution of $51,000 quicker. In addition, a solo 401(k) plan has a catch-up contribution of $5500, which is not the case with a SEP IRA. Furthermore, a solo 401(k) plan has a Roth component and allows plan participants to borrow up to $50,000 or 50% of their account value whatever is less.
IRA Financial Group’s special SEP IRA rollover self-directed solo 401(k) Plan is designed to allow a SEP IRA rollover to a solo 401k plan without incurring any tax or penalty on the rollover.
The IRA Financial Group was founded by a group of top law firm tax and ERISA lawyers who have worked at some of the largest law firms in the United States, such as White & Case LLP and Dewey & LeBoeuf LLP.
IRA Financial Group is the market’s leading “Checkbook Control” Self Directed IRA and Solo 401k Plan Facilitator. We have helped thousands of clients take back control over their retirement funds while gaining the ability to invest in almost any type of investment, including real estate tax-free and without custodian consent!
To learn more about the IRA Financial Group please visit our website at http://www.irafinancialgroup.com or call 800-472-0646.
Houston, Texas (PRWEB) December 08, 2013
Houston’s inbound marketing agency, Adhere Creative, celebrates the success of their No Shave November fundraising campaign, which helped generate $1710 for prostate cancer research and awareness.
No Shave November is an annual, month-long event aimed at raising awareness for men's health. The participants pledge to refrain from shaving for the entire month in an effort to raise funds for charities of associated illnesses.
This year, the Adhere Creative team launched Adhere Noshember, their own No Shave November campaign to raise money for the cause. The proceeds of the campaign was awarded to Stop & Smell the Rosies, a non-profit organization supporting charities that help fund treatment and awareness of individuals suffering from unfortunate life-changing strife like Prostate Cancer.
The campaign encouraged donations of all sizes. Adhere Creative offered 30 minute free marketing strategy consultation sessions with the team as a prize for generous $50 donations. The campaign raised a total of $855 from various donors and was duly matched by the marketing agency for a grand total of $1710.
“We are honored to receive such a gracious contribution from Adhere Creative,” said Joan Board, Founder of Stop & Smell the Rosies. “Support like this brings faith and hope to those who are burdened by hardships and life-threatening illnesses like Prostate Cancer, and we’re deeply touched by Adhere Creative’s effort to make a difference.”
Nathan Yerian, Director of Strategy at Adhere Creative, explained that the company’s vision for success involves giving back to the community by supporting causes dear to the hearts of its team.
“Launching a No Shave November campaign provided a great opportunity for us to prove our commitment to this vision.” Said Yerian. “We were excited to use out bread growing skills to touch lives and help those in need.”
Adhere Creative is an inbound marketing agency dedicated to developing brand identities and comprehensive marketing strategies that produce measurable results. In addition to charitable campaigns like No Shave November, the marketing agency also organizes the annual One Award, which entails a full and free brand makeover for a selected non-profit organization.
For more information, visit Adhere Creative on the web at http://www.adherecreative.com.
Read the full story at http://www.prweb.com/releases/adhere/no-shave-november/prweb11402285.htm
RARITAN, N.J., Dec. 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care (BSC), exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative.1 MCD is a disorder in which lymphocytes, a certain type of white blood cells, are over-produced and lead to enlargement of lymph nodes.2,3
These data supported the recent regulatory filings of siltuximab in the United States and European Union. Interim findings from a separate Phase 2 study (MCD2002) reinforce the safety profile of siltuximab.4 The studies were featured in an oral presentation (MCD2001) and poster presentation (MCD2002) at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans, USA.
"MCD is a devastating disease that weakens the immune system and may lead to life-threatening infections," said Raymond S. Wong, MBChB, M.D., Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong and lead study investigator. "These results are encouraging and from my perspective support the potential for siltuximab as a new treatment for these patients who previously had no approved treatment options."
The MCD2001 study found more than one-third of patients in the siltuximab arm had a durable tumor and symptomatic response to treatment, compared to none of the patients who received placebo plus BSC (34 percent versus 0 percent). The median time to treatment failure was not reached for patients who received siltuximab plus BSC versus 134 days for who received placebo plus BSC. In looking at the response rate to treat MCD-related symptoms, 25 percent of patients who received siltuximab plus BSC had durable complete symptom resolution, defined as 100 percent of reduction of baseline overall symptom scores for at least 18 weeks, compared to none of the patients who received placebo plus BSC.1
The safety profile, defined by frequencies of treatment-emergent adverse events (AEs), Grade 3 or higher AEs and serious adverse events (SAEs), was similar between siltuximab and placebo even with the duration of treatment being twice as long for those in the siltuximab arm. The most frequently reported Grade 3 or higher AEs with siltuximab were fatigue (9 percent), night sweats (8 percent), hyperkalemia (high levels of potassium in blood), hyperuricemia (high levels of uric acid in blood), localized edema (swelling at a specific site in the body), hyperhidrosis (excessive sweating), neutropenia (an abnormally low number of neutrophils, a type of white blood cell), thrombocytopenia (a decrease of platelets in the blood), hypertension (high blood pressure), and weight increase (4 percent each).1
In addition, an interim analysis of the Phase 2 study MCD2002 was presented on December 7 in a poster titled:
- An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman's Disease (Abstract #1806)
This ongoing extension study assessed the safety of long-term treatment with siltuximab in 19 patients with MCD whose disease was controlled for an extended period of time in a Phase 1 study. At the time of study analysis (January 2013), the patients had been treated with siltuximab for up to 7.2 years (median of 5.1 years) with no cumulative toxicity observed. At the data cutoff for this interim analysis of the extension study, all patients were alive and maintaining disease control. Findings suggest prolonged siltuximab treatment exhibited a tolerable side effect profile.4
During a median treatment duration of 5.1 (range 3.4-7.2) years, the most commonly reported AEs included upper respiratory tract infection (89 percent); nausea (63 percent); vomiting (58 percent); diarrhea (53 percent); hypercholesterolemia (high levels of cholesterol in blood) (47 percent); hypertriglyceridemia (high levels of triglycerides in blood), pain in arms and legs, headache, rash and abnormal liver function (each 42 percent). However, the majority of them were low grade. Two patients had at least one serious infection during the Phase 1 study, and none were reported during the Phase 2 extension study.4
These abstracts were also published online in the December 6 supplemental volume of Blood.
MCD2001 Study Design1
MCD2001 is a Phase 2 multi-national, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of siltuximab plus best supportive care (BSC) versus placebo plus BSC in 79 patients with MCD who are HIV-negative and HHV-8-negative. MCD2001 is the first randomized study in MCD. Patients were randomized 2:1 to receive either siltuximab plus BSC or placebo plus BSC until protocol-defined treatment failure, after which patients taking the placebo could cross over to un-blinded siltuximab. Half of the patients on placebo (13 out of 26) crossed over to siltuximab.
The primary efficacy endpoint of the study was durable tumor and symptomatic response, defined as partial response or complete response (Cheson criteria) by independent radiological review, and improvement/stabilization in MCD-related symptoms for at least 18 weeks. Secondary endpoints included additional predefined efficacy measures and safety. The primary analysis occurred after the last treated patient completed assessments at 48 weeks.
Baseline MCD symptoms included fatigue (86 percent), malaise (61 percent), night sweats (52 percent), peripheral sensory neuropathy (nerve damage in the peripheral nervous system) (38 percent), anorexia and pruritus (itching) (37 percent each). Median treatment duration was 375 days with siltuximab versus 152 days with placebo, with 64 percent versus 27 percent completing 48 weeks of treatment, respectively.
About Multicentric Castleman's Disease (MCD)MCD is a rare disorder with high morbidity in which lymphocytes, a certain type of white blood cells, are over-produced and lead to enlargement of lymph nodes.2,3 MCD can also affect lymphoid tissue of internal organs, causing the liver, spleen, or other organs to enlarge.5 Signs and symptoms are driven by dysregulated Interleukin-6 (IL-6) production.1,6 Many common symptoms include fever, weakness, fatigue, night sweats, weight loss, loss of appetite, nausea, vomiting and nerve damage that leads to numbness and weakness.3 Some symptoms can be life threatening.7,8 Infections, renal failure, and malignancies including malignant lymphoma and Kaposi's sarcoma are common causes of death in patients with MCD.7,8 Currently, there are no approved treatments in the U.S. or EU for MCD.
Unlike "unicentric" Castleman's disease, which is localized and affects only a single area or group of lymph nodes,6 patients with MCD have more than one group of lymph nodes in different anatomical areas that are affected.9 Unicentric disease can be treated by surgically removing the diseased lymph node,10 while multicentric disease is usually much more difficult to treat.11 Currently, the focus of care is to reduce lymph node masses and to attempt to put the disease in remission through a combination of treatments, including corticosteroids, chemotherapy and immunotherapy.7,8 While such treatments may initially help, the disease often returns.
Castleman's disease is formally diagnosed through a biopsy.5 The number of people diagnosed with Castleman's disease is unknown, but the disease is known to be rare.12
About SiltuximabSiltuximab is an investigational, anti Interleukin-6 (IL-6) chimeric monoclonal antibody that targets and binds to human IL-6. IL-6 is a multifunctional cytokine produced by various cells such as T cells, B cells, monocytes, fibroblasts and endothelial cells. Dysregulated, or imbalanced, overproduction of IL-6 from activated B cells in affected lymph nodes has been implicated in the pathogenesis of MCD.6 Information about ongoing studies with siltuximab can be found on clinicaltrials.gov.
On September 3, 2013, Janssen announced simultaneous submissions of a Biologic License Application (BLA) to the United States Food and Drug Administration (U.S. FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for siltuximab for the treatment of patients with MCD who are HIV-negative and HHV-8-negative. The U.S. FDA accepted the submission and granted siltuximab priority review, and the EMA has granted Accelerated Assessment of the MAA for siltuximab. Siltuximab has been granted orphan drug status in MCD in the U.S. and EU. With the regulatory submissions, a Named Patient Program (NPP) was made available in the U.S. for siltuximab to provide pre-approval treatment access to eligible patients with MCD.
About Janssen Research & Development, LLCAt Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include disease area strongholds that focus on hematologic malignancies and prostate cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualized use of our therapies; as well as safe and effective identification and treatment of early changes in the tumor microenvironment. While we continually strive to find new real-life solutions for cancer patients, the Janssen Pharmaceutical Companies can provide a broad offering throughout the cancer journey — from prevention, diagnosis, and treatment — to the return to wellness.
Janssen Research & Development is part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.
1 Wong RS et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease. Oral presentation presented at: 55th American Society of Hematology (ASH) Annual Meeting; Dec. 7-11, 2013; New Orleans, LA.
2 American Cancer Society. What is Castleman disease? Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-what-is-castleman-disease. Accessed August 2013
3 Memorial Sloan Kettering Cancer Center. Uncommon Lymphoproliferative Disorders. Available from: http://www.mskcc.org/cancer-care/adult/rare-hematologic-disorders/uncommon-lymphoproliferative-disorders. Accessed August 2013.
4 Van Rhee F et al. An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman's Disease. Poster presentation presented at: 55th American Society of Hematology (ASH) Annual Meeting; Dec. 7-11, 2013; New Orleans, LA.
5 American Cancer Society. How is Castleman disease diagnosed? Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-diagnosis Accessed October 2013
6 El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497-511.
7 Peterson, B. Seminars in Oncology. Multicentric Castleman's disease. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8296200 Accessed October 2013
8 Greiner, T. Hematology Am Soc Hematol Educ Program. Atypical Lymphoproliferative Diseases. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11701539 Accessed October 2013
9 National Center for Advancing Translational Sciences. Multicentric Castleman's Disease. Available from: http://rarediseases.info.nih.gov/gard/9644/idiopathic-multicentric-castlemans-disease/resources/1 Accessed November 2013.
10 American Cancer Society. Treatment of localized (unicentric) Castleman disease. Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-treating-treating-localized. Accessed October 2013
11 American Cancer Society. Treatment of multicentric Castleman disease. Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-treating-treating-multicentric. November October 2013
12 American Cancer Society. What are the key statistics about Castleman disease? Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-key-statistics . Accessed November 2013
Note: Data in this release correspond to ASH Abstracts 1806 and 505.
U.S. Media Inquiries:Ilona RubinoPhone: 1-215-793-7227Mobile : 1-484-678-8698
EU Media Inquiries:Satu GlawePhone: 49-2638-947-9218
Investor Relations:Stan PanasewiczPhone: 1-732-524-2524
Louise MehrotraPhone: 1-732-524-6491
U.S. Medical Inquiries:1-800-526-7736
SOURCE Janssen Research & Development, LLC
NEW ORLEANS, Dec. 8, 2013 /PRNewswire-USNewswire/ -- A series of studies presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncover promising efficacy and safety results for several unique compounds and combination treatments, each aimed at improving long-term outcomes for patients with blood disorders ranging from clots to cancer.
Recent advances have helped hematologists better understand the cellular activity of blood cancers and non-malignant blood disorders. These developments have paved the way for the development of new molecules that selectively target disease-causing mechanisms and, as a result, may improve treatment success. Furthermore, researchers are now identifying combinations of existing therapies, in addition to new targeted therapies, that can more effectively prevent disease progression while reducing the toxic side effects of current standard treatments.
The encouraging efficacy of these novel therapies in patients has allowed researchers to focus on developing strategies that aim to increase patients' long-term survival while reducing toxicity. For example, several new investigational therapies being discussed in today's press conference have been designed to target specific proteins on the cell surface that fuel cancer growth. Additional studies look at existing anti-cancer compounds in new ways to better understand drug interactions, reduce toxicity, increase response rates and improve outcomes among patients with disease that might be resistant to current treatments. Yet another study harnesses the therapeutic value of clot-busting snake venom, translating it into a powerful new investigational therapy.
"Our research efforts in hematology continue to focus on identifying 'next-generation' treatments that will make treatment easier and more tolerable for patients with blood disorders," said Joseph Mikhael, MD, moderator of the press conference and Associate Dean of the School of Graduate Medical Education, Deputy Director of Education at Mayo Clinic Cancer Center and Associate Professor of Medicine at Mayo Clinic College of Medicine in Scottsdale, Arizona. "These clever approaches – from selectively interfering with cancer-driving proteins to targeting mechanisms of abnormal cell growth to exploring the utility of purified snake venom as an anticoagulant – exemplify the exciting progress we're making in improving the treatment of hematologic cancers and blood diseases."
This press conference will take place on Sunday, December 8, 2013, at 8:00 a.m. CST.
The First In Vitro and In Vivo Assessment of Anfibatide, a Novel Glycoprotein Ib Antagonist, in Mice and in a Phase I Human Clinical Trial 
Using purified snake venom, a team of researchers developed a unique new anti-thrombotic compound known as anfibatide, which is designed to target a specific receptor on the surface of platelets that is instrumental to the formation of blood clots (glycoprotein Ib complex, or GPIb). Researchers initially assessed the investigational compound's clot-busting effects in several in vitro laboratory tests, and then evaluated functional activity in mouse models. After reaching the conclusion that anfibatide may be effective as an anti-thrombotic drug, the team then evaluated its safety and efficacy in a Phase I clinical trial. When tested in 94 healthy volunteers, the compound effectively prevented platelets from sticking together specifically through the GPIb complex, but did not otherwise affect platelet count or significantly prolong bleeding. At the doses investigated, no anti-anfibatide antibodies were detected, and the treatment caused no serious adverse events or deaths among study participants.
"The concept that we can harness something potentially poisonous in nature and turn it into a beneficial therapy is very exciting," said one of the senior investigators Heyu Ni, MD, PhD, of St. Michael's Hospital, the University of Toronto, and Canadian Blood Services. "The fact that this compound only targets the platelet receptor involved in clotting and does not appear to have significant side effects makes it a particularly promising anti-thrombotic therapy."
Dr. Ni will present this study during an oral presentation at 4:30 p.m. CST on Monday, December 9, in Rooms 278-282 of the Ernest N. Morial Convention Center.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients With Multicentric Castleman's Disease 
Drugs known as monoclonal antibodies, engineered to target disease-harboring proteins on the surface of cells or to block growth signals in the microenvironment, have demonstrated strong efficacy and safety, and have become more common treatments for blood cancers. Given this success, researchers are experimenting with the use of monoclonal antibodies in rare diseases with limited treatment options. One such disease is multicentric Castleman's disease (MCD), a potentially fatal, incurable disorder with high morbidity believed to be partially mediated by the overproduction of a specific cell signaling molecule known as interleukin-6 (IL-6) that results in the dangerous overgrowth of cells in the lymph nodes.
This study evaluated the safety and efficacy of siltuximab, an investigational monoclonal antibody designed to block the function of IL-6 in an attempt to ameliorate uncontrolled cell growth and control other inflammatory disease symptoms. Investigators enrolled 79 MCD patients in a Phase II trial who were randomized to receive either siltuximab or placebo, in combination with best supportive care, to assess rates of remission and improvement in symptoms. Roughly one-third of patients treated with siltuximab achieved a durable tumor and symptom response whereas none of the placebo-treated patients showed a response. While disease symptoms completely resolved in one-quarter of the siltuximab-treated patients for a median of 1.3 years, this was never observed in patients treated with placebo, indicating that siltuximab led to prolonged duration of disease control. Rates of adverse events were similar between the treatment and placebo groups, despite a two-fold longer duration of treatment in the siltuximab group.
"Based on these promising results, it appears that patients treated with this highly targeted monoclonal antibody approach can potentially experience far superior and equally safe responses than those observed with current conventional treatments," said study author Raymond S. Wong, MBChB, MD, of the Prince of Wales Hospital and the Chinese University of Hong Kong. "If siltuximab gains regulatory approval, this experimental therapy could become the first globally approved treatment for this incurable disease and could potentially transform how patients are treated in the future."
Dr. Wong will present this study during an oral presentation at 2:45 p.m. CST on Monday, December 9, in La Nouvelle Ballroom AB of the Ernest N. Morial Convention Center.
Initial Phase III Results of the First (Frontline Investigation of Revlimid + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Stem Cell Transplantation (SCT) 
This Phase III trial was designed to compare the efficacy and safety of a combination of two oral drugs, lenalidomide and low-dose dexamethasone (Rd), to a standard combination therapy including melphalan, prednisone, and thalidomide (MPT) used worldwide to treat patients with newly diagnosed multiple myeloma (NDMM). A total of 1,623 NDMM patients ineligible for stem cell transplant due to age or other factors were randomized into three treatment arms: continuous Rd until disease progression, Rd for 72 weeks, or MPT for 72 weeks. After a median follow-up period of 37 months, the study met its primary endpoint by demonstrating that those patients treated with continuous Rd were more than a quarter (28%) less likely to experience disease progression or death than those patients treated with MPT. Further, patients in both Rd treatment arms showed improvements in overall survival, overall response rate, and duration of response. While the safety profiles of the two treatment regimens were similar, patients treated with Rd showed fewer secondary hematologic malignancies than those treated with MPT.
"Traditionally, newly diagnosed patients have received initial, short bursts of treatment, while continuous treatment was reserved for relapsed patients. However, we believe that these new results will help encourage more research on the efficacy and safety of continuous treatment for newly diagnosed patients to help maximize their chances for overall long-term survival," said study author Thierry Facon, MD, of Service des Maladies du Sang, Hôpital Claude Huriez, and CHRU Lille in France. "For some patients with low-risk myeloma, this continuous regimen could make this disease a manageable, chronic condition."
Dr. Facon will present this study during the Plenary Scientific Session at 2:55 p.m. CST on Sunday, December 8, in Hall F of the Ernest N. Morial Convention Center.
Gemtuzumab Ozogamicin (GO) in Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) by Reducing Relapse Risk – Results From the Randomized Phase III Children's Oncology Group (COG) Trial, AAML0531 
For children diagnosed with cancer, their post-treatment relapse rate is one of the major indicators of their potential for long-term survival. This research program evaluated whether adding the monoclonal antibody gemtuzumab (GO) to standard chemotherapy might improve event-free survival without causing excessive toxicity and mortality in children with acute myeloid leukemia (AML). In this Phase III trial, more than 1,000 children (10 years old on average) were treated with GO or a standard treatment regimen, followed by additional chemotherapy for low-risk patients and stem cell transplants for high-risk patients. Overall, compared with standard regimens, the addition of GO was associated with better disease-free survival (61 vs. 55%) and reduced relapse risk (33 vs. 41%), though it did not significantly improve overall survival (74 vs. 70%).
"These results are encouraging, as combining gemtuzumab with chemotherapy appears to reduce the risk of disease relapse, which translates to an improved event-free survival in children with AML," said study author Alan S. Gamis, MD, MPH, of Children's Mercy Hospital and Clinics in Kansas City, Mo. "Importantly, the therapy seemed to have a particularly lasting effect among those patients who achieved remission in the course of treatment. Though gemtuzumab was previously removed from the market due to lack of clinical value in earlier trials, this growing body of positive data in populations of critical need may be sufficient to bring it back as a commercial treatment option."
Dr. Gamis will present this study during an oral presentation at 10:30 a.m. CST on Monday, December 9, in La Nouvelle Ballroom C of the Ernest N. Morial Convention Center.
Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3 [LBA-5]
While lenalidomide is an effective treatment commonly used for multiple myeloma and certain B-cell lymphomas, research has yet to fully explain how it works. Using a combination of experiments focused on cellular protein activity, investigators discovered that lenalidomide has a unique mechanism of action for a drug. Specifically, investigators concluded that the drug promotes binding of two lymphoid transcription factors, IKZF1 and IKZF3, to the CRBN-DDB1 ubiquitin ligase. This interaction leads to the selective degradation of these transcription factors, which are essential for multiple myeloma cells. Consistant with this mechanism, the researchers also observed that lenalidomide decreased IKZF1 and IKZF3 levels in human T cells, leading to activation of IL-2 expression, a known effect of the drug.
"Lenalidomide is a unique tool in our treatment arsenal, as we have used it effectively for many years but have not yet fully understood its mechanisms. This research offers a clear illustration of its specific activity in multiple myeloma," said study author Jan Krönke, MD, of Brigham and Women's Hospital in Boston. "Based on these mechanisms, we may be able to design new drugs in our efforts to improve patient outcomes in lymphomas or even in other diseases."
Dr. Krönke will present this study during the Late-Breaking Abstracts Session at 7:30 a.m. CST on Tuesday, December 10, 2013, in Hall F of the Ernest N. Morial Convention Center.
American Society of Hematology 55th Annual MeetingThe study authors and press program moderator will be available for interviews after the press conference or by telephone. Additional press briefings will take place throughout the meeting on leukemia research, new transplantation strategies, novel compounds in development, and progress against sickle cell disease and thalassemia. For the complete annual meeting program and abstracts, visit www.hematology.org/2013abstracts. Follow @ASH_hematology and #ASH13 on Twitter and like ASH on Facebook at for the most up-to-date information about the 2013 ASH Annual Meeting.
The American Society of Hematology (ASH) (www.hematology.org) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.
SOURCE American Society of Hematology
OKLAHOMA CITY--(BUSINESS WIRE)-- Groupon is offering a local deal to experience the natural beauty of Robbers Cave State Park in Wilburton, Okla. There are three options -- lodge room, one-bedroom cabin or two-bedroom cabin -- available at http://www.groupon.com/deals/robbers-cave-state-park-7.
At one time this state park was a hideout for Jesse James and Belle Starr. The wooded hills, rugged caves and remote location amid the Sans Bois Mountains made it an ideal place for the infamous to disappear after robbing a train. Today, this same natural landscape attracts a different sort of adventurer — rock climbers, cave explorers and all outdoor enthusiasts. The park's 8,200 acres include three fishable lakes that teem with trout and perch, and the trails offer scenic trips for hikers, mountain bikers and equestrians.
Shoppers can choose from three options:
- $44 for a one-night stay in a lodge room ($88 value)
- $46 for a one-night stay in a one-bedroom cabin ($93 value)
- $54 for a one-night stay in a two-bedroom cabin ($108 value)
A variety of deals, especially curated for gifting, can be found by visiting the Groupon Gift Shop or by searching the site. In addition to a collection of great products, gifts of local experiences can be given nationwide.
Groupon (NASDAQ: GRPN) is a global leader of local commerce and the place you start when you want to buy just about anything, anytime, anywhere. By leveraging the company’s global relationships and scale, Groupon offers consumers a vast marketplace of unbeatable deals all over the world. Shoppers discover the best a city has to offer on the web or on mobile with Groupon Local, enjoy vacations with Groupon Getaways, and find a curated selection of electronics, fashion, home furnishings and more with Groupon Goods.
Groupon is redefining how traditional small businesses attract, retain and interact with customers by providing merchants with a suite of products and services, including customizable deal campaigns, credit card payment processing capabilities, and point-of-sale solutions that help businesses grow and operate more effectively. To search for great deals or subscribe to Groupon emails, visit www.Groupon.com. To download Groupon's five-star mobile apps, visit www.groupon.com/mobile. To learn more about the company’s merchant solutions and how to work with Groupon, visit www.GrouponWorks.com.
GrouponErin Yeager, email@example.com
More Press ReleasesView Older Stories
Groupon and Young Chefs Academy Offer Kids Cooking Classes
The World’s Leading Wedding Dress Manufacturer And Retailer MerleDress Release Its 2014 Prom Dresses For This Holiday Shopping Season
Schneider Homes Announces the Grand Opening of their New Hawkesbury Community in Kent, Washington
Discovering 11 Tips On How To Remove Body Hair Naturally – V-kool
Eamonn McCrystal Releases New Christmas Album
Van Nuys Movers Provide Tips for Packing and Moving Fragile Objects in Van Nuys!
Life Insurance For Over 50 And Over Is Important In Retirement Planning
Michigan Minimally Invasive Surgeon Releases Hernia Surgery Resource on MichiganSurgery.com
Swimovate USA Announces Winner of their Swim Watch Giveaway with Gametiime
No Medical Exam Life Insurance Should Be Bought After Taking Into Consideration Some Important Issues
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Pretium Resources, Inc. of Class Action Lawsuit and Upcoming Deadline -- PVG
Skip Dieting – Increase Metabolism to Lose Weight: Health Nutrition News Video Explains How to Speed Up Metabolism
Fitments Information and Specs Provider, SizeItUp, Adds Brand Alloy Technologies To Database
Family Gift Ideas Have Been Released on Kids Activities Blog
$99 Small Business Payroll Software Now Available to SMEs Nationwide
Claggett & Sykes Law Firm Obtain Binding Arbitration Award Against American Family Insurance
Carlton’s Training Solutions Demonstrates How to Avoid Workplace Bullying
Titan Poker Stages Month of Holiday Poker Promotions
Small Firms Services Celebrate 15 Years with New Office
Titan Poker Stages Month of Holiday Poker Promotions
Titan Poker Stages Month of Holiday Poker Promotions
22Social's Marketing Expert & CEO Rene Banuelos, to Interview G+ Go To Gal, Yifat Cohen
One Direction Tickets 2014: TicketProcess.com Adds Additional Inventory of One Direction Tour Tickets Online Today
Wise Advice: 5 Things Top-Funded Companies Have in Common
Cold Craft, Inc., a Silicon Valley Heating Company, Prepared to Supply Space Heaters for Customers Awaiting Equipment or Repairs
Prominent Social Security Disability Lawyer in Topeka, KS, Parmele Law Firm, Introduces No-Cost Case Consultations
Are You Ready For The Winter Weather As Predicted By The Farmer's Almanac?
Holiday Insurance Savings: How Consumers Are Using the Power of the Internet to Find New Ways to Lower Rates in Less Time
Fashionable Wedding Jackets Released by Dressv.com
TradeRush Brings New Custom Market Analysis and News Feed for Traders, According to ForexMinute
Revolutionary Neck Comfort Support
iPad Mini Screen Repair Now Easier with ScrewMat for iPad Mini WIFI
Drug Rehabilitation Center Is Now Servicing the Hammocks, Florida, with Addiction Treatment Services
Forex Profit Multiplier: Review Examining Bill Poulos's New Forex Trade Alert Software Released
Garmin Forerunner 620 Needs A Foot Pod For Indoor Pace Says HRWC
Back Pain Treatment with Dr. Allen’s Device Helps Naturally While Attempts to Use Nerve Ablation For Pain Back Relief May Harm, Highlights Fine Treatment
Announcement: GuitarControl.com Releases “Lead Guitar Lesson - Blues-Rock Guitar Licks in the style of AC DC”
World Auto Group Announces Its NJ Car Dealers Offer New CarFax 1-Owner Vehicles in December
11 Auctions at OnlineAuctionUSA.com in Week of Dec. 9
ZoomTrader Offers New Comprehensive Trading Assets for Traders, Reports ForexMinute
A New “16 Home Remedies For Neck Pain” Article Teaches People How To Get Rid Of Neck Pain Naturally – Healthreviewcenter
Get to Know 18 Tips On How to Remove Dead Skin Cells – V-kool
bestwebdesignagencies.co.uk Names December 2013 Listings of Top Gui Design Firms in the United Kingdom
10 Top PHP Development Companies in the UK Declared by bestwebdesignagencies.co.uk for December 2013
Ten Best Windows Phone Apps Firms in the United Kingdom Published in December 2013 by bestwebdesignagencies.co.uk
10 Best PSD to HTML Conversion Agencies in the UK Announced by bestwebdesignagencies.co.uk for December 2013
Ten Best Flash Design Companies in the United Kingdom Disclosed in December 2013 by bestwebdesignagencies.co.uk
Ten Best Flash Design Companies in the United Kingdom Disclosed in December 2013 by bestwebdesignagencies.co.uk
new-zealand.bestwebdesignagencies.com Names December 2013 Ratings of Best iPhone Development Agencies in New Zealand
5 Best iPhone Development Consultants in the Netherlands Issued by netherland.bestwebdesignagencies.com for December 2013